company-logoRoivant Sciences Ltd.$16.12
%
Analyst Rating: Hold

Stock Details

CEO

Matthew Gline

Sector

Healthcare

Industry

Biotechnology

Full Time Employees

908

Address

11-12 St. James's Square, London, SW1Y 4LB

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Top Competitors

Income Statement  

Financials

Selected Year

Revenue Estimates

EPS Estimates

Net Income Estimates

Price target for Roivant Sciences Ltd.  $16.12

EPS

Revenue

Institutional Holder

Congress Tracker 

Insider Trading of Key Employees

Financial News: ROIV